The article presents a study which compares the toxicity and efficacy profile of 96-hour and three-hour infusion schedule of paclitaxel in treating metastatic breast cancer (MBC). The study evaluated the response of patients with MBC on chemotherapy regimens using bidimensional measurements. Results show that patients' response rate on both schedules was similar. It concludes that paclitaxel was active in MBC either in 96-hour and three-hour infusion schedules.